

Memo no.: 2026-013
Date: 22-July-2026
Memo to: Clients
Re: ***UPDATE: Fluoxetine and Metabolite, Serum/Plasma – Change in Methodology***

As per the recent memo dated June 22, 2026, the performing laboratory has implemented a change in methodology for [Fluoxetine and Metabolite, Serum/Plasma](#). The method has been changed from high-performance liquid chromatography with fluorescence detection (HPLC-FLD) to an ultra-performance liquid chromatography with tandem mass spectrometry detection.

The lab's LIS build is now complete to reflect this change, effective immediately.

Reference ranges will be reported only for the combined Fluoxetine and Norfluoxetine Metabolites:

Result	Revised Reference Intervals
Norfluoxetine	(No range)
Fluoxetine	(No range)
Fluoxetine + Norfluoxetine	388 – 1695 nmol/L

Revised HL7 codes:

Order Choice Name	Fluoxetine and Metabolite, Serum/Plasma	
Order Code	FLUOX	
Result Name	Units	Result Code
NORFLUOXETINE	nmol/L	2943
FLUOXETINE	nmol/L	2942
FLUOXETINE + NORFLUOXETINE	nmol/L	66340

If you have further questions, please contact Client Care at 416-422-3000 ext. 300 or info@iclabs.ca

Dr. Shashank Tilak, Ph.D., DCC
Laboratory Director
416-422-3000 ext. 221
shashtilak@iclabs.ca